Altogether, silibinin can inhibit cancer hallmarks against NSCLC cells and also inhibited PD-L1 expression through EGFR-mediated PI3K/AKT and JAK2/STAT5 signaling mechanisms (Figure 7). The gene discussed is STAT5B; the disease is cancer.